Abbott Displays Its Life-Changing POC Tests and Diagnostic Tools at MEDLAB Middle East
|
By LabMedica International staff writers Posted on 26 Jan 2022 |

At the 2022 edition of MEDLAB Middle East, Abbott (Lake Forest, IL, USA) showcased its portfolio of life-changing diagnostic tools and medical devices for point-of-care testing that help manage patients with COVID-19, diabetes cardiovascular disease and their comorbidities.
Within its COVID-19 test portfolio, Abbott displayed its ID NOW COVID-19 molecular point-of-care platform that combines the benefits of speed and accuracy for the fastest molecular results in the market. The ID NOW COVID-19 test returns positive results in 13 minutes or less to enable immediate clinical decisions during the first patient visit. The easy to use ID NOW platform is designed for near-patient, point-of-care use in a variety of healthcare settings. Abbott highlighted its Panbio COVID-19 IgG/IgM Rapid Test Device, an in vitro diagnostic rapid test for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 in human serum, plasma, venous and fingerstick whole blood, alongside the Panbio COVID-19 Ag Rapid Test Device which can identify potentially contagious patients with or without symptoms in 15 minutes.
Also on display was the Afinion 2 System, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care for physician offices and clinics, eliminating the need to send patients to the lab or spend time tracking down their results. The Afinion 2 System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP, and can reliably transfer test information to a HIS or LIS system. The analyzer and test cartridges have been precision engineered with each test cartridge containing an integrated sample collection device and all necessary reagents for a single test.
At MEDLAB 2022, Abbott demonstrated the i-STAT Family of products for a broad range of clinical settings, including the lightweight, portable and easy to use i-STAT 1 blood analyzer which operates with the advanced technology of i-STAT test cartridges. Together, they create the i-STAT System - a point-of-care testing platform that provides healthcare professionals with diagnostic information when and where it's needed. Abbott also displayed the i-STAT Alinity, an easy-in-use, portable bloody analyzer that delivers real-time, lab-quality diagnostic test results. The i-STAT Alinity is the i-STAT family's most advanced testing solution and features a more intuitive interface that simplifies the testing process even further, allowing for minimal operator training.
Related Links:
Abbott
Latest Medlab 2022 News
- EUROIMMUN Presents EUROPattern Microscope Live with EUROLabOffice 4.0 Software for Ultrafast Automated Microscopy
- PerkinElmer Exhibits Automated Nucleic Acid Extraction Solutions at MEDLAB Middle East
- Diagast Presents Latest Immunohaematology Solutions at MEDLAB Middle East
- Siemens Brings Its Latest Innovations in Laboratory Diagnostics to MEDLAB Middle East 2022
- Bioperfectus Showcases Its Molecular Diagnostic Products for Infectious Diseases at MEDLAB 2022 Online
- Seegene Showcases New STARlet-AIOS All-in-One Solution for All Molecular Testing at MEDLAB Middle East
- LumiraDx Presents Its Next-Generation POC Diagnostics Platform and Fast Lab Solutions at MEDLAB Middle East
- Randox Highlights Its Innovative Diagnostic Products Revolutionizing Healthcare at MEDLAB Middle East
- Beckman Coulter Demonstrates Newly Launched DxA 5000 Fit Workflow Automation System at MEDLAB Middle East
- Horiba Presents Comprehensive Range of Hematology, Hemostasis and Clinical Chemistry Analyzers at MEDLAB Middle East
- MGI Tech Launches New MGISP-Smart 8 Automated Sample Preparation System at MEDLAB Middle East
- GC Labs Highlight Its “Smart Lab” Concept at MEDLAB Middle East 2022
- MEDLAB Middle East and Arab Health 2022 Edition Return as Co-Located Events for Healthcare and Laboratory Industries
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
Bile duct strictures can arise from cancer or benign disease, but their location within ducts connecting the liver, gallbladder, and intestines complicates evaluation. Standard biopsy and cytology may... Read moreAdaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
PCR amplification during next-generation sequencing (NGS) library preparation can introduce variability, often requiring manual quantification and risking over-cycling artifacts. The issue is especially... Read more
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Rapid Urine Test Speeds Antibiotic Selection for UTIs
Urinary tract infections are a common reason for antibiotic prescribing and have led to more than 800,000 hospital admissions across England in the past five years, according to National Health Service data.... Read more
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read morePathology
view channel
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
Lunit (Seoul, South Korea), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta (Montreal, QC, Canada), a global contract research organization (CRO) laboratory serving... Read more









